Leptin, an adipocyte hormone involved in energy homeostasis, is important in reproduction and pregnancy. Questions yet to be addressed include the source of higher leptin during pregnancy and its relationship to pregnancy outcome and fetal growth. The objective of this study was to investigate the relationship between placental leptin gene expression, placental leptin protein concentration and maternal plasma leptin concentration among control pregnant women, women with pre-eclampsia and women with growth-restricted infants. We also investigated the relationship between placental leptin expression and the placental expression of enzymes involved in cellular lipid balance: fatty acid translocase (CD36), carnitine palmitoyltransferase I (CPT-1B) and lipoprotein lipase (LPL). Placental leptin expression, placental protein and maternal plasma concentration were higher in pre-eclampsia than in controls but not in women with growth-restricted infants. Placental leptin expression and placental protein were higher in the preterm pre-eclamptic subjects, whereas maternal leptin was higher in the term pre-eclamptic subjects. The placental gene expression of CD36, CPT-1B and LPL were not different among the groups. This study suggests that despite similar failed placental bed vascular remodelling in pre-eclampsia and intrauterine growth restriction (IUGR), leptin gene expression is higher only in preterm pre-eclampsia.
Introduction
Pre-eclampsia is a common pregnancy-specific syndrome (3-5% of pregnancies), which is one of the major causes of maternal and perinatal morbidity and mortality worldwide. It places great demands for maternity care because the onset and clinical course are unpredictable, and there is currently no predictive test available. The aetiology is unknown, but the placenta is essential for the disease process. The only treatment is delivery, which often causes iatrogenic prematurity. Pre-eclampsia is diagnosed by the new appearance of increased blood pressure and proteinuria in late pregnancy (Roberts and Lain, 2002) . Pre-eclampsia can be considered as a twostage disease (Roberts, 2003) . The first stage is a reduction in fetalplacental perfusion, frequently secondary to abnormal implantation. The second stage is the maternal syndrome. However, the first stage does not always result in the second stage. Placental bed biopsies examined with conventional histological techniques indicate similar reduced vascular remodelling and abnormal implantation in preeclampsia, intrauterine growth restriction (IUGR) and preterm births that are not associated with infection (Khong et al., 1986; Arias et al., 1993) . IUGR is not invariably associated with pre-eclampsia even if non-perfusion perturbing abnormalities such as infection and fetal anomalies are excluded.
We propose that reduced placental perfusion generates fetalplacental signals that influence maternal metabolism and physiology which may influence nutrient delivery and affect fetal growth. We hypothesize that some women cannot tolerate this signal and will develop pre-eclampsia, whereas an inadequate signal results in IUGR without the maternal syndrome. The hormone leptin may act as such a pregnancy signal. Leptin is secreted by adipose tissue and during pregnancy by the placenta (Masuzaki et al., 1997) . The proposed roles for leptin in pregnancy include the regulation of fetal growth, placental angiogenesis, growth and immunomodulation, as well as mobilization of maternal fat (Hoggard et al., 2001 ). According to placental perfusion studies, 98.4% of placental leptin is released into the maternal circulation (Linnemann et al., 2000) . Total and free leptin concentrations are higher in maternal blood during pregnancy and further elevated in pre-eclampsia (McCarthy et al., 1999; Laivuori et al., 2000; Teppa et al., 2000) . Therefore, leptin could be one of the fetalplacental signals altering maternal metabolism to benefit the fetus by mobilizing nutrients.
The objective of this study was to quantify and investigate the relationship between placental leptin gene expression, placental leptin protein and maternal plasma leptin among control pregnant women, women with pre-eclampsia and women with growth-restricted infants. We further investigated the relationship between placental leptin expression and the placental expression of enzymes involved in cellular lipid balance: fatty acid translocase (CD36), a transporter of the long-chain fatty acids (Febbraio et al., 2001) ; carnitine palmitoyltransferase I (CPT-1B), a mitochondrial fatty acid transport protein and regulator of β-oxidation (Wang et al., 1999) ; and lipoprotein lipase (LPL), a regulator of triglyceride hydrolysis (Herrera, 2002) .
Materials and methods

Subjects and sample acquisition
With the permission of the Institutional Review Board (IRB), we studied placenta samples from 79 women who provided written informed consent. Twenty-one pre-eclamptic women were matched as a group by maternal age, gestational age at delivery, pre-pregnancy BMI, parity and race with 20 women with uncomplicated pregnancies (controls for pre-eclampsia) (Table I) . Similarly, 20 women with IUGR infants were matched as a group with 18 women with uncomplicated pregnancies (controls for IUGR) (Table I) . Placenta samples were acquired as a part of Prenatal Exposures and Pre-eclampsia Prevention (PEPP) project and were collected between 12 April 1998 and 16 November 2000. Women with pre-existing diabetes were excluded from the study population. Smoking status was available from only 9 women in the preeclampsia group, 17 women in controls for pre-eclampsia, 19 women in the IUGR group and 18 women in the controls for IUGR. Therefore, we were not able to match groups by smoking status. Three women in the pre-eclampsia group, 9 women in controls for pre-eclampsia, 14 women in the IUGR group and 8 women in the controls for IUGR were smokers. Systolic and diastolic blood pressures were not significantly different between the pre-eclampsia group and controls for pre-eclampsia before 20 weeks of gestation but were significantly elevated at delivery in the pre-eclampsia group (Table I) . Systolic and diastolic blood pressures were not significantly different between the IUGR group and controls for IUGR before 20 weeks of gestation or at delivery (Table I ). Ten women in the pre-eclampsia group delivered preterm (before 37 weeks of gestation) compared with eight controls for pre-eclampsia (P = 0.62). All women in the IUGR group and controls for IUGR delivered at term. Glucocorticoids were administered to one woman in the pre-eclampsia group and to two controls for pre-eclampsia who delivered before 33 weeks of gestation (P = 0.61). The birthweight centiles were corrected for gestational age, race and sex for our population and were lower in the pre-eclampsia group and the IUGR group compared with controls (Table I) . Four women in the pre-eclampsia group (19%) delivered IUGR infants, and all these deliveries were preterm (40% of the preterm pre-eclampsia).
All pre-eclamptic women met the criteria of hypertension, proteinuria and hyperuricaemia. Hypertension was defined as an increase of 30 mmHg systolic or 15 mmHg diastolic blood pressure compared with values obtained before 20 weeks of gestation or an absolute blood pressure of 140 and/or 90 mmHg after 20 weeks of gestation, if earlier blood pressures were unknown. Among the pre-eclamptic women, 71.4% had an absolute blood pressure of 140 mmHg systolic or 90 mmHg diastolic in addition to the diagnostic incremental blood pressure increase. Proteinuria was defined as >300 mg per 24-h collection, >+2 on a voided or >+1 on a catheterized random urine specimen or >0.3 for the urine protein/creatinine ratio. Hyperuricaemia was defined as >1 SD above the mean value for the gestational age at which the sample was obtained. IUGR was defined as the birthweight below tenth centile for the gestational age corrected for race and sex for our population.
Placenta samples were obtained at the time of vaginal delivery (73 samples) or Caesarean section (6 samples). Tissues were rinsed in saline, frozen in liquid nitrogen and then stored at -80°C until use. Maternal EDTA plasma samples were obtained at the time of admission for delivery. Samples were stored at -80°C for later analysis.
RNA isolation and reverse transcription
RNA was extracted using RNAwiz™ reagent (Ambion, Austin, TX, USA) according to the manufacturer's instructions. The amount of RNA was measured spectrophometrically by the absorbance at 260 nm. The purity of the RNA was estimated by the ratio of the absorbance at 260/280 nm. The quality of the RNA samples was determined with denaturing agarose gels and staining with ethidium bromide. The placenta total RNA (400 ng) was reverse transcribed to cDNA in 20 μl volume using Taqman Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, USA). Final reaction conditions were ×1 Taqman buffer, 5.5 mM MgCl, 500 μU of each dNTP, 2.5 μM random hexamers, 0.4 U/μl ribonuclease inhibitor and 1.25 U/μl MultiScribe reverse transcriptase. Reaction mixture was incubated at 25°C for 10 min, 48°C for 30 min and heat-inactivated at 95°C for 5 min. The human placenta total RNA (2 μg) (FirstChoise™ Total RNA; Ambion) was reverse transcribed to complementary cDNA in 100 μl volume using Taqman Reverse Transcription Reagents (Applied Biosystems) to create standard curves in the real-time RT-PCR step. The efficiency of the reverse transcription was estimated to be 70%.
Real-time RT-PCR
To monitor gene expression, we used semi-quantitative real-time PCR analysis. All PCR reactions were performed using an ABI Prism 7700 Sequence Detection System (Applied Biosystems). The threshold cycle (Ct) reflects the cycle number at which the fluorescence generated in the reaction crosses a preselected threshold and is inversely related to the concentration of cDNA prior to amplification. We compared Ct values of the samples with a standard curve constructed by serial dilutions of the human placenta total RNA.
Primers and probes
We used SYBR Green chemistry to analyse leptin, CD36 and CPT-1B gene expression and amplified b-actin as an endogenous control. Primers were chosen using the Primer Express software version 1.5a (Applied Biosystems). To avoid the amplification of the genomic DNA, all the target gene forward and reverse primers were selected to be in different exons, except b-actin, in which case the forward primer was selected at the junction between two exons. We conducted standard nucleotide BLAST to confirm the specificity of the primers, and we checked the absence of single nucleotide variations. The LPL gene expression was analysed using Taqman chemistry, and b-actin was amplified as an endogenous control. We used minor groove-binding (MGB) DNA oligonucleotide (TaqMan MGB probe), which forms hyper-stabilized duplexes with cDNA. Primers and probe for LPL gene were chosen using the Primer Express software version 1.5a (Applied Biosystems) (Table II) following the user-bulletin guidelines for the design of MGB probes. All primers were from University of Pittsburgh DNA Synthesis Facility. LPL TaqMan MGB probe was bought from Applied Biosystems Custom Oligo Synthesis Service (Foster City, CA). Commercial pre-developed assay reagents (×20 primer and MGB probe mix) were used to detect b-actin (Applied Biosystems) and to obtain a normalized LPL gene value.
PCR amplification
In PCR reactions for leptin, CD36, CPT-1B and b-actin (25 μl), we used ×1 SYBR® Green PCR Master mix (Applied Biosystems), 300 nM of each primer and 3.5 ng (1:20 dilution, 5 μl volume) cDNA template. In PCR reactions for LPL (25 μl), we used ×1 TaqMan® PCR Master mix (Applied Biosystems), 900 nM of each primer, 250 nM TaqMan MGB probe and 3.5 ng cDNA template. In PCR reactions for b-actin used to normalize LPL gene expression (25 μl), we used ×1 TaqMan® PCR Master mix (Applied Biosystems), ×1 Human β-actin Control Mix (Applied Biosystems) and 3.5 ng cDNA template. The thermal cycling conditions were 50°C for 2 min (for carry-over prevention with Uracil-N-glycosylase) and an initial denaturation step at 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and 60°C for 1 min.
Melting curve analysis of SYBR Green assays
Because SYBR Green binds to any double-stranded DNA, the specificity of the product and absence of primer dimers and other non-specific products were confirmed with the additional run for melting curves after PCR amplification. The SYBR Green fluorescence of generated products was continuously monitored throughout temperature ramp from step 60°C to 95°C for 19 min 59 s. After data recording, a Sequence Detection Software version 1.7a (Applied Biosystems) multicomponent file was exported to Dissociation Curves 1.0 software (Applied Biosystems) for the melting curve analysis. The selected conditions and primers resulted in amplification of a single species of cDNA.
Analysis of cDNA samples
All samples were run in duplicate in a 96-well plate for the target gene and b-actin. For each sample, the amount of the target gene and the endogenous control was determined from the standard curves run in the same plate. The target gene amount was divided by the endogenous control amount to obtain the normalized target gene value.
Real-time RT-PCR standard curve construction
The standard curves using the four concentrations were performed in duplicate for each target gene and b-actin. Dilutions were made to produce a standard curve covering the concentration range 70-70 000 pg of total placenta RNA per well for leptin and CD36, 350-70 000 pg for CPT-1B and 700-70 000 pg for LPL. Inter-assay variation for standards were 4.6% for leptin, 2.2% for CD36, 5.4%
for CPT-1B, 1.2% for LPL, 3.6% for b-actin (SYBR Green chemistry) and 1.4% for b-actin (TaqMan chemistry). The standard curves displayed a linear correlation of 0.96-1.00. The efficiency of the reaction (E) was calculated using the formula E = 10 1/m -1, where m is the slope of the standard curve. The mean E was 78% for the leptin reactions, 64% for the LPL reactions, 57% for the CD36 reactions, 61% for the CPT-1B reactions, 67% for the b-actin reactions (SYBR Green) and 66% for the b-actin reactions (TaqMan).
Quantification of plasma leptin
Total plasma leptin was quantified by radioimmunoassay using the commercial RIA from Linco Research Inc. (St. Charles, Missouri, catalog # HL-81K). All samples were run in duplicate. The average coefficient of variation between runs was 7.1%.
Preparation of placental homogenates and placental leptin quantification
Homogenates of placental tissue were prepared from the rinsed and flash-frozen placental tissue discussed previously. Briefly, placental homogenates were prepared by homogenizing the tissue in 1:2.5 (grams tissue : millilitre volume) in HEPES-Mannitol-Magnesium buffer (300 mM Mannitol, 1 mM MgSO 4 ·7H 2 O and 10 mM HEPES) (pH 7.4) at 4°C. The homogenate was centrifuged at 23 000 × g for 40 min, and the supernatant was collected and assayed for total protein and leptin. Placental leptin protein was quantified using an enzyme-linked immunosorbent assay (ELISA) from Linco Research Inc. (St. Charles, Missouri, catalog # EZHL-80SK). All samples were run in duplicate. The inter-assay coefficient of variation was <10%. Placental leptin protein was normalized to the total protein concentration of the supernatant of the placental homogenate. Protein quantification was determined by the Bradford method and standardized to known quantities of bovine serum albumin (BSA).
Statistical analysis
Statistical analysis was performed using Stat-View 4.5 software (Abacus Concepts, Berkeley, CA, USA). Data are presented as mean ± SEM unless otherwise indicated. Parametric and non-parametric tests were used as appropriate for the continuous clinical data. Categorical data were analysed using Chisquare or Fisher's exact test. Comparisons of the gene expression and leptin measurements between the four groups were conducted using analysis of variance (ANOVA) and Fisher's protected least significant difference (PLSD) post hoc test. The square root transformation was performed to normalize the distribution of the data. The Spearman rank correlation coefficient was used to analyse leptin gene expression and birthweight centiles. Statistical significance was accepted at P < 0.05 for all comparisons.
Results
The ratio of placental leptin/b-actin mRNA was higher in pre-eclampsia cases (4.99 ± 1.38) compared with controls for pre-eclampsia (1.65 ± 0.32, P = 0.015), IUGR cases (1.27 ± 0.30, P = 0.002) and controls for IUGR (2.37 ± 0.77, P = 0.028) (Table III) . Similarly, the concentration of placental leptin protein and maternal plasma leptin were higher in the pre-eclampsia cases compared with controls for pre-eclampsia (Table III) , and there was no difference in placental leptin protein and maternal plasma leptin between the IUGR cases and the controls for IUGR (Table III) .
The ratio of placental leptin/b-actin mRNA was higher in those preeclamptic patients who delivered preterm [<37 weeks of gestation, n = 10, gestational age = 34.8 ± 0.45 weeks (mean ± SE)] (7.23 ± 2.02 leptin/ b-actin ratio) compared with pre-eclamptic patients who delivered at term (n = 11, 38.2 ± 0.43 weeks, P < 0.0001 versus preterm preeclampsia) (2.95 ± 1.74 leptin/b-actin ratio, P = 0.005), controls for pre-eclampsia who delivered preterm (n = 8, 2.00 ± 0.67 leptin/b-actin ratio, P = 0.007) and controls for pre-eclampsia who delivered at term (n = 12, 1.42 ± 0.31 leptin/b-actin ratio, P = 0.001) ( Figure 1A ). Furthermore, when divided into term and preterm deliveries, the concentration of placental leptin protein was higher in the preterm preeclamptic cases (1.29 ± 0.22 ng/mg protein) compared with the term controls (0.59 ± 0.16 ng/mg protein, P = 0.04) ( Figure 1B ). In contrast, maternal plasma leptin was not different between term and pre-term pre-eclampsia (P = 0.48) and was higher in the term preeclamptic cases (51.3 ± 8.6 ng/ml) compared with the term controls (28.4 ± 3.6 ng/ml, P = 0.02) ( Figure 1C ), while differences between preterm pre-eclamptics and their controls did not achieve statistical significance (P = 0.09).
Placental leptin gene expression correlated negatively with the birthweight centiles in the pre-eclampsia cases (Spearman r = -0.45, P = 0.03), whereas no correlation was seen in the IUGR cases (Spearman r = -0.03, P = 0.89). Placental leptin protein and maternal plasma leptin did not correlate with birthweight centile in the pre-eclamptic cases or IUGR cases.
There were no significant differences in ratios of CPT-1B/b-actin, CD36/b-actin or LPL/b-actin mRNA ratios between pre-eclampsia cases, IUGR cases and their respective control groups (data not shown).
Discussion
The role of increased maternal leptin during human pregnancy is unclear; however, it has been hypothesized to be important in fetal growth, and we speculate that it may serve as a possible signal to alter maternal metabolism to benefit the fetus. In this study, we found that placental leptin expression, placental leptin protein and plasma leptin are all higher in women with pre-eclampsia but not different among women with IUGR infants compared with controls, and the elevation in placental leptin expression and protein is primarily in women with preterm pre-eclampsia; however, the increase in plasma leptin is primarily in the women with term pre-eclampsia.
We found a significant increase in leptin gene expression in the placental tissue of women with preterm pre-eclampsia compared with pregnancies complicated by term pre-eclampsia or IUGR or with gestational age-matched controls. Furthermore, leptin gene expression was not different between the two control groups with 3-week difference in the gestational age, and there were no differences in frequency of glucocorticoid administration, which is known to affect leptin expression (Miell et al., 1996) . Higher placental leptin expression has been reported in pre-eclampsia previously, but no distinction was made between preterm and term (Li et al., 2004) . In addition, similar to our study, Bersinger and co-workers reported no differences in placental leptin protein concentrations in term pre-eclampsia compared with controls (Bersinger et al., 2002) . Furthermore, we report finding an increase in maternal plasma leptin in pre-eclampsia similar to several previous studies (McCarthy et al., 1999; Laivuori et al., 2000; Teppa et al., 2000; Sagawa et al., 2002) .
Why are placental leptin gene expression and leptin protein increased in preterm pre-eclampsia? It has been suggested that placental production of leptin is augmented in pre-eclampsia because of placental hypoxia, which is a consequence of reduced placental perfusion (Mise et al., 1998) . Indeed, it has been shown in trophoblast-derived BeWo cells that leptin gene expression is up-regulated by hypoxia through a transcriptional mechanism likely to involve distinct hypoxia-responsive cis-acting sequences in the promoter (Grosfeld et al., 2001) . However, our finding that placental leptin gene expression is not different in IUGR pregnancies that are also presumably hypoxic compared with controls suggests that there are likely additional contributing factors to placental leptin expression. One such factor could be insulin. A large (3-to 5-fold) augmentation in placental leptin message and protein has been reported in insulin-treated diabetic women (Lepercq et al., 1998) . In addition, prolonged exposure to insulin increases plasma leptin concentrations in humans (Kolaczynski et al., 1996; Malmström et al., 1996) . Pre-eclampsia is a state of hyperinsulinaemia and increased insulin resistance (Kaaja et al., 1999) , and it is tempting to speculate that maternal hyperinsulinaemia is also important in the up-regulation of placental leptin gene expression in this condition. Another possibility is that inflammatory stimuli may up-regulate leptin expression (Sarraf et al., 1997) . The inflammatory response is already well developed in normal pregnancy and further elevated in pre-eclampsia (Redman et al., 1999) , and leptin gene expression is higher in inflammation and plays a key role in immune response and T-cell activation (Zarkesh-Esfahani et al., 2004; Otero et al., 2005; Sennello et al., 2005) . The fact that the main difference occurs in preterm pre-eclampsia may suggest a greater importance for inflammation in preterm pre-eclampsia. It is also possible that the placental cells relevant to leptin production are not hypoxic in IUGR. The syncytiotrophoblast is the site of placental leptin production (Senaris et al., 1997) , and in at least severe IUGR, the intervillous blood to which syncytiotrophoblast is exposed is hyperoxic as a result of reduced oxygen extraction (Kingdom and Kaufmann, 1999) .
The placenta is a target of leptin action as well as a source for leptin synthesis (Hassink et al., 1997; Henson et al., 1998) . Leptin and its receptors co-exist in the syncytiotrophoblast (Challier et al., 2003) . The location of transmembrane leptin-receptor isoforms on placental cells facing the maternal circulation implies that receptors are likely to bind maternal circulating leptin (Challier et al., 2003) . Furthermore, a recent study has demonstrated that leptin is capable of stimulating placental amino acid transport that is likely to be of benefit to fetal growth (Jansson et al., 2003) . However, placental leptin gene expression was inversely correlated with infant birthweight centile in the pre-eclamptic cases but not the IUGR cases or controls. In addition, maternal plasma leptin and placental leptin protein did not correlate with birthweight centile in any of the groups. These relationships suggest that the effect of leptin, if any, on fetal growth is not simple; and the investigation of the effect of leptin on specific pathways important to fetal growth (such as amino acid or lipid transport) is likely to provide greater insight into its biological relevance. To this end, we examined the gene expression of three enzymes involved in cellular lipid balance: CD36, a transporter of the long-chain fatty acids; CPT-1B, a regulator of β-oxidation; and LPL, a regulator of triglyceride hydrolysis. However, in contrast to leptin, we did not observe any differences in the expression of these enzymes between the four groups. This study indicates that placental leptin expression and protein production are higher in pre-eclampsia, particularly preterm, and this is in contrast to IUGR in the absence of pre-eclampsia. Furthermore, the increase in placental leptin likely contributes to increases in maternal plasma leptin. Lastly, the action of leptin on placental function is likely to be significant; however, this area requires further investigation. (PE preterm) or term (PE term) and controls for pre-eclampsia who delivered preterm (Control preterm) or term (Control term). *P = 0.007 compared with preterm control, P = 0.001 compared with the term control and P = 0.005 compared with term PE; **P = 0.04 compared with the term control; ***P < 0.02 compared with term control. Lines indicate means. Data were normalized by taking its square root before statistical analysis [Analysis of variance (ANOVA), Fisher's protected least significant difference (PLSD) post hoc test]. 
